Thomas Dayspring: A Decade on Repatha – Stable CAD, No Ischemic Events
Thomas Dayspring, Lipidologist at Early Medical, shared on LinkedIn:
”Anecdotal Study of 1 — Me — I have chronic stable CAD (CAC > 300 15 years ago). With that and other risk factors I had, I easily would have qualified for inclusion in the VESALIUS CV Trial. Fortunately, as soon as PCSK9i came on the market I went on Repatha and now a decade later I am still here – no ischemic events. The day after I got the CAC, I had an invasive coronary angiogram which demonstrated wide open lumens: disease was all in arterial wall. Here is data from GLACOV that shows evolocumab not only kept me alive without any CV issues but likely is causing regression. My apoB on Repatha monotherapy is 50 mg/dL and LDL-C 45 mg/dL. THANK YOU REPATHA, Amgen National Lipid Association European Atherosclerosis Society, American Society for Preventive Cardiology (ASPC).”
Stay updated with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera